Skip to main content

UCB Medicines: Clinical Studies and Scientific Research Publication

Publications

Filter
This page contains links to basic science and clinical research published on UCB medicines and disease areas of focus. The information is limited to products that have been approved for use by the U.S. Food and Drug Administration (FDA) and may contain information that is not part of the FDA-approved Prescribing Information (eg, doses, uses, devices, populations). UCB, Inc. does not recommend or endorse the use of its products in a manner not consistent with the approved Prescribing Information. Please see the Full Prescribing Information for each product when making clinical decisions.

Select product(s):
Select topic(s):
Phase:

*Includes seizure clusters and acute or prolonged seizures

137 result(s)

phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Improvement in work productivity among psoriatic arthritis patients treated with biologic or targeted synthetic drugs: a systematic literature review and meta-analysis in Arthritis Research and Therapy 

Laure Gossec, Brittany Humphries, Megan Rutherford et al.  February 15, 2024
phase 4

BRIVIACT® (brivaracetam) CV

Focal Onset Seizures
View

Conversion to brivaracetam monotherapy in clinical practice: a retrospective study

Simona Lattanzi, Nicoletta Foschi, Chiara Martellino et al.  February 01, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Validity and score interpretation of the 12-item Psoriatic Arthritis Impact of Disease: an analysis of pooled data from two phase 3 trials of bimekizumab in patients with psoriatic arthritis 

Gossec Laure, Orbai Ana-Maria, Laura C Coates et al.  January 31, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Bimekizumab for the treatment of psoriatic arthritis. 

Tanaka Yoshiya, Shaw Stevan et al.  January 21, 2024
pre clinical

RYSTIGGO® (rozanolixizumab-noli)

Generalized Myasthenia Gravis
View

Interactions of the anti-FcRn monoclonal antibody, rozanolixizumab, with Fcγ receptors and functional impact on immune cells in vitro

Qureshi S Omar, Sutton J Emma, Rosemary F Bithell et al.  January 19, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Comparative efficacy and safety of bimekizumab in psoriatic arthritis: a systematic literature review and network meta-analysis 

Philip J Mease, Gladman D. Dafna, Joseph F. Merola et al.  January 13, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies

Xenofon Baraliakos, Deodhar A. Atul, Desiree van der Heijde et al.  January 11, 2024
phase 3

BIMZELX® (bimekizumab-bkzx)

Psoriatic Arthritis
View

Comparative Effectiveness of Bimekizumab in Psoriatic Arthritis: A Model-Based Meta-Analysis of American College of Rheumatology Response Criteria

Alan Maloney, Pinky Dua, Ghada F. Ahmed et al.  December 10, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Work productivity in patients with axial spondyloarthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review and meta-analysis

Rudwaleit Martin, Mørup Michael Frank, Brittany Humphries et al.  November 30, 2023
phase 3

BIMZELX® (bimekizumab-bkzx)

Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
View

Comparative efficacy and safety of bimekizumab in axial spondyloarthritis: a systematic literature review and network meta-analysis.    

Deodhar Atul, Machado M. Pedro, Mørup Michael Frank et al.  November 08, 2023